KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 90 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $712,620 | -10.6% | 74,000 | -16.5% | 0.00% | 0.0% |
| Q2 2023 | $797,400 | -1.0% | 88,600 | -13.6% | 0.00% | 0.0% |
| Q1 2023 | $805,650 | +0.7% | 102,500 | -13.4% | 0.00% | -33.3% |
| Q4 2022 | $799,708 | -6.9% | 118,300 | +99.7% | 0.00% | 0.0% |
| Q3 2022 | $859,000 | +17.3% | 59,229 | -20.4% | 0.00% | +50.0% |
| Q2 2022 | $732,000 | +46.4% | 74,400 | +119.5% | 0.00% | +100.0% |
| Q1 2022 | $500,000 | +76.7% | 33,900 | +58.4% | 0.00% | 0.0% |
| Q4 2021 | $283,000 | -54.3% | 21,400 | -39.7% | 0.00% | 0.0% |
| Q3 2021 | $619,000 | -19.0% | 35,500 | +11.3% | 0.00% | -50.0% |
| Q2 2021 | $764,000 | -6.8% | 31,900 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $820,000 | +113.0% | 31,900 | +57.1% | 0.00% | +100.0% |
| Q4 2020 | $385,000 | +23.4% | 20,300 | +16.0% | 0.00% | 0.0% |
| Q4 2019 | $312,000 | +53.7% | 17,500 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $203,000 | – | 17,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |